Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YLPXW
ADC Name
WO2021147993A1 ADC-8
Synonyms
WO2021147993A1 ADC 8
   Click to Show/Hide
Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Drug-to-Antibody Ratio
3.93
Structure
Antibody Name
hRS7
  Antibody Info 
Antigen Name
Tumor-associated calcium signal transducer 2 (TACSTD2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2021147993A1 ADC-8 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 76
%
COLO 205 cells
Colon adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 76.00% (Day 28) Moderate TROP2 expression (TROP2 ++)
Method Description
Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model Colo205 CDX model
In Vitro Model Colon adenocarcinoma COLO 205 cells CVCL_0218
References
Ref 1 Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof; 2021-07-29.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.